Developer docs
API playgroundTry for free, no card

Search company profiles

Broncus Technologies

Full company profile

uuid0000xyx

Namestring
Broncus Technologies
Websiteurl
broncus.com
Company typeenum
Private
Founded yearint
1997
Short descriptiontext

Broncus Technologies (Broncus Medical) is a medical technology company developing minimally-invasive devices for diagnosing and treating lung diseases such as emphysema, serving pulmonology healthcare providers in China, Europe, North America, and worldwide markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
interventional pulmonology devices, lung disease treatment, minimally invasive medical devices, respiratory care technology, emphysema treatment devices
Industry4 codes
1Bronchoscopy & Interventional Pulmonology
CodeHLAKANAJPrimaryYes
2COPD & Chronic Bronchitis Management
CodeHLAKANAEPrimaryNo
3General Pulmonology Practice
CodeHLAKANAAPrimaryNo
4Pulmonary Function & Respiratory Diagnostic Centers (PFT/Spirometry)
CodeHLAFAKAJPrimaryNo
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Interventional Pulmonology Medical Devices
Social media profiles2 records
Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Broncus Technologies is a medical technology company that develops and manufactures minimally-invasive medical devices for the diagnosis and treatment of emphysema and other lung diseases. The company's offerings target interventional pulmonology applications and are sold to hospitals, pulmonologists, and healthcare systems across China, Europe, North America, and additional worldwide markets under the "Broncus Medical" brand (堃博医疗).

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Broncus Medical Interventional Pulmonology Devices
CategoryInterventional Pulmonology Medical Devices
Description

Minimally-invasive medical devices developed by Broncus Technologies for the diagnosis and treatment of emphysema and other lung diseases. The devices are sold to hospitals, pulmonologists, and healthcare providers under the Broncus Medical brand across China, Europe, North America, and additional worldwide markets.

2Uptake Medical Lung Disease Portfolio
CategoryInterventional Pulmonology Medical Devices
Description

Lung disease treatment technologies integrated into Broncus Technologies' product portfolio following the 2016 acquisition of Uptake Medical. Adds bronchoscopic lung therapy capabilities to the company's interventional pulmonology device lineup for healthcare providers.

No data
Peers10 records
1Pulmonx
TypeDirect peer
Description

Direct competitor in interventional pulmonology, focused on lung disease treatments including emphysema and COPD. Pulmonx markets Zephyr endobronchial valves, comparable to Broncus's minimally-invasive lung solutions.

2Intuitive Surgical
TypeBroad incumbent
Description

Broader incumbent in surgical robotics and a strategic Broncus investor (Series B lead 2018). Operates Ion robotic bronchoscopy platform directly competing in the same procedural category.

3Olympus (Spiration)
TypeBroad incumbent
Description

Large medical device incumbent with respiratory and bronchoscopy product lines acquired via Spiration. Provides overlapping minimally-invasive lung disease solutions with global distribution.

4Boston Scientific
TypeBroad incumbent
Description

Broncus investor (2004 round) and broad interventional medical device incumbent with significant respiratory and pulmonary involvement across multiple geographies.

5Penumbra
TypeDirect peer
Description

Public thrombectomy-focused medical device company with adjacent peripheral/embolization pulmonary applications; comparable small-cap interventional medtech business model.

6MicroPort Scientific
TypeRegional player
Description

China-headquartered interventional medical device company with overlapping respiratory and pulmonary offerings; comparable dual China/US-listed medtech business model.

7Inspire Medical Systems
TypeEmerging player
Description

Public medical device company addressing respiratory/sleep disorders through minimally-invasive neurostimulation; comparable small-cap interventional medtech trajectory.

8Merit Medical Systems
TypeBroad incumbent
Description

Broadly diversified interventional medical device manufacturer with respiratory/pulmonary diagnostics and therapy products, comparable business model in commercializing specialty devices globally.

9ERBE Elektromedizin
TypeRegional player
Description

Specialized interventional medical device company focused on pulmonary and respiratory surgical equipment; comparable in niche interventional lung device focus but regional (Europe-centric).

10Cook Medical
TypeBroad incumbent
Description

Private diversified medical device manufacturer with interventional pulmonology and respiratory diagnostic products, comparable in procedural lung solutions for pulmonologists.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors31 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Broncus Technologies

Interventional Pulmonology Medical Devicesbroncus.com

Broncus Technologies (Broncus Medical) is a medical technology company developing minimally-invasive devices for diagnosing and treating lung diseases such as emphysema, serving pulmonology healthcare providers in China, Europe, North America, and worldwide markets.

Broncus Technologies firmographics

Firmographics
Name
Broncus Technologies
Website
https://broncus.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
51–100 employees
Short description
Broncus Technologies (Broncus Medical) is a medical technology company developing minimally-invasive devices for diagnosing and treating lung diseases such as emphysema, serving pulmonology healthcare providers in China, Europe, North America, and worldwide markets.
Ownership category
akta.pro rank

Broncus Technologies industry classification

Industry
Product category
Interventional Pulmonology Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Bronchoscopy & Interventional Pulmonology (HLAKANAJ)
akta.pro secondary industries
COPD & Chronic Bronchitis Management (HLAKANAE), General Pulmonology Practice (HLAKANAA), Pulmonary Function & Respiratory Diagnostic Centers (PFT/Spirometry) (HLAFAKAJ)

Keywords

  • Interventional pulmonology devices
  • Lung disease treatment
  • Minimally invasive medical devices
  • Respiratory care technology
  • Emphysema treatment devices

Where Broncus Technologies is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Markets served

Broncus Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Broncus Technologies product offering

Product offering

Core offering

Broncus Technologies is a medical technology company that develops and manufactures minimally-invasive medical devices for the diagnosis and treatment of emphysema and other lung diseases. The company's offerings target interventional pulmonology applications and are sold to hospitals, pulmonologists, and healthcare systems across China, Europe, North America, and additional worldwide markets under the "Broncus Medical" brand (堃博医疗).

Differentiator

Problem solved

Functional benefit

Products and services

  • Broncus Medical Interventional Pulmonology Devices Minimally-invasive medical devices developed by Broncus Technologies for the diagnosis and treatment of emphysema and other lung diseases. The devices are sold to hospitals, pulmonologists, and healthcare providers under the Broncus Medical brand across China, Europe, North America, and additional worldwide markets.
  • Uptake Medical Lung Disease Portfolio Lung disease treatment technologies integrated into Broncus Technologies' product portfolio following the 2016 acquisition of Uptake Medical. Adds bronchoscopic lung therapy capabilities to the company's interventional pulmonology device lineup for healthcare providers.

Companies that use Broncus Technologies

Customer profile

Segments1 record

Ideal customer profiles1 record

Broncus Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Broncus Technologies competitors and assessment

Company assessment

Direct peers

  • Pulmonx: Direct competitor in interventional pulmonology, focused on lung disease treatments including emphysema and COPD. Pulmonx markets Zephyr endobronchial valves, comparable to Broncus's minimally-invasive lung solutions.
  • Penumbra: Public thrombectomy-focused medical device company with adjacent peripheral/embolization pulmonary applications; comparable small-cap interventional medtech business model.

Broad incumbents

  • Intuitive Surgical: Broader incumbent in surgical robotics and a strategic Broncus investor (Series B lead 2018). Operates Ion robotic bronchoscopy platform directly competing in the same procedural category.
  • Olympus (Spiration): Large medical device incumbent with respiratory and bronchoscopy product lines acquired via Spiration. Provides overlapping minimally-invasive lung disease solutions with global distribution.
  • Boston Scientific: Broncus investor (2004 round) and broad interventional medical device incumbent with significant respiratory and pulmonary involvement across multiple geographies.
  • Merit Medical Systems: Broadly diversified interventional medical device manufacturer with respiratory/pulmonary diagnostics and therapy products, comparable business model in commercializing specialty devices globally.
  • Cook Medical: Private diversified medical device manufacturer with interventional pulmonology and respiratory diagnostic products, comparable in procedural lung solutions for pulmonologists.

Regional players

  • MicroPort Scientific: China-headquartered interventional medical device company with overlapping respiratory and pulmonary offerings; comparable dual China/US-listed medtech business model.
  • ERBE Elektromedizin: Specialized interventional medical device company focused on pulmonary and respiratory surgical equipment; comparable in niche interventional lung device focus but regional (Europe-centric).

Emerging players

  • Inspire Medical Systems: Public medical device company addressing respiratory/sleep disorders through minimally-invasive neurostimulation; comparable small-cap interventional medtech trajectory.

Market position

Customer concentration

Broncus Technologies social profiles

Digital presence

Broncus Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Broncus Technologies leadership team

Management profile

Number of profiles

Profiles2 records

Broncus Technologies funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors31 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Broncus Technologies M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Broncus Technologies

What does Broncus Technologies do?

Broncus Technologies is a medical technology company that develops and manufactures minimally-invasive medical devices for the diagnosis and treatment of emphysema and other lung diseases. The company's offerings target interventional pulmonology applications and are sold to hospitals, pulmonologists, and healthcare systems across China, Europe, North America, and additional worldwide markets under the "Broncus Medical" brand (堃博医疗).

Is Broncus Technologies a public or private company?

Broncus Technologies is a private company. It is classified as public and is currently operating.

When was Broncus Technologies founded?

Broncus Technologies was founded in 1997. It employs 51 to 100 people.

Where is Broncus Technologies based?

Broncus Technologies is headquartered in Mountain View, United States, in the North America region.

Who are Broncus Technologies's main competitors?

Direct peers on record are Pulmonx and Penumbra. Broad incumbents are Intuitive Surgical, Olympus (Spiration), Boston Scientific, Merit Medical Systems and Cook Medical. Regional players are MicroPort Scientific and ERBE Elektromedizin. Inspire Medical Systems is listed as an emerging player.

Does Broncus Technologies have an API?

No public API is recorded for Broncus Technologies.

What industry is Broncus Technologies in?

Broncus Technologies's product category is Interventional Pulmonology Medical Devices. Its primary akta.pro industry code is HLAKANAJ, Bronchoscopy & Interventional Pulmonology, with a secondary code of HLAKANAE, COPD & Chronic Bronchitis Management. Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBroncus Announced Long-Term Follow-Up Data on InterVapor, Showing Stable Long-Term Efficacy in PatientsBroncus announced long-term follow-up data on their InterVapor device for COPD treatment at the 23rd ERS International Congress in September 2023, with the study initiated in 2017 as a multi-country post-market registry. The 36-month data showed no serious adverse events associated with the bronchoscopic thermal vapor ablation treatment, with patients demonstrating better pulmonary function, exercise tolerance, and symptom scores compared to standard medications. InterVapor has received marketing approval in China, the European Union, France, Germany, the United Kingdom, and Italy, and is included in GOLD treatment guidelines for five consecutive years.PR NewswireIntroducing BIOSTAR® cutting-edge Conventional TBNA (cTBNA) and Endobronchial ultrasound (EBUS) TBNA (EBUS-TBNA) needle: Revolutionizing Minimally Invasive Diagnostic techniquesBroncus Medical Inc. announced the launch of its BioStar® Transbronchial Aspiration Needle, a device designed for conventional and endobronchial ultrasound TBNA procedures to improve lung cancer diagnosis and staging. The product is currently available in Europe and other global markets, though it remains under pre-market review by the US FDA and is not yet approved for use in the United States.PR NewswireBroncus Medical (02216.HK) Announces Interim Results for 2023Broncus Medical (02216.HK) announced interim results for H1 2023, reporting product sales of US$5.234 million, a 63% increase year-over-year, with mainland China sales surging 114% to US$4.251 million. The company advanced its interventional pulmonology pipeline, including positive 6-month clinical trial data for its BroncAblate radiofrequency ablation system showing a 99.35% technical success rate in 126 lung cancer patients. Net loss narrowed to -US$14.73 million as the company expanded commercialization of its navigation and therapeutic products, including InterVapor approved across 21 Chinese provinces.PR NewswireBroncus Medical (02216.HK) Announces Annual Results for 2022Broncus Medical announced its 2022 annual results, reporting product sales of US$9.41 million (up 8% year-over-year) with Mainland China sales growing 50% to US$5.81 million, while also advancing multiple products through regulatory approvals in China, the EU, and India. The company spent US$19.17 million on R&D and has 18 major product candidates in various development stages as it works to consolidate its position in precision interventional diagnosis and treatment of pulmonary diseases. Strategic partnerships with Healium Medical, Shanghai United Family Healthcare, Eternal Asia, Guangzhou Institute of Respiratory Health, and AstraZeneca were also disclosed.PR NewswireBRONCUS'S DISPOSABLE NEBULIZING MICRO-CATHETER FOR ENDOSCOPE WAS APPROVED FOR MARKETING IN CHINA AND ITS APPLICATIONS IN DRUG-DEVICE COMBINATION WILL BE BROADENEDBroncus Holding Corporation received marketing approval from the Zhejiang Medical Products Administration for its Mist Fountain Nebulizing Micro-Catheter on October 28, 2022. The product is a patented drug-device combination tool designed to deliver liquid medicine directly to lung lesions via endoscopes, offering uniform drug distribution and reduced tissue damage risk. This approval marks the company's first achievement in this field and paves the way for future applications in bronchoscopy anesthesia, tuberculosis treatment, and targeted oncology drug delivery.PR NewswireBroncus (02216.HK) announced interim resultsBroncus reported interim results for the six months ended June 30, 2022, showing a 12.8% increase in operating revenue to USD 3.218 million and a 62.8% narrowing of losses. The company expanded its R&D pipeline with a First-in-Man clinical trial for its Targeted Lung Denervation system and strengthened its global presence through strategic cooperation with Israeli firm Healium Medical Ltd.PR NewswireBRONCUS COMPLETED SURGERIES ON THE FIRST GROUP OF PATIENTS USING ITS InterVapor®, THE THERMAL VAPOR TREATMENT SYSTEM, AFTER APPROVED FOR MARKETING IN CHINABroncus Medical (02216.HK) has completed surgeries on the first group of patients using its InterVapor® thermal vapor treatment system in China, following NMPA approval received in March 2022, marking the official clinical commercialization entry of the device in China for treating chronic obstructive pulmonary disease (COPD). InterVapor® is the first NMPA-approved and globally first thermal vapor energy ablation system for COPD treatment, representing a breakthrough innovation that fills a significant treatment gap for severe emphysema patients, with at least 106 million COPD patients in China alone. The company has obtained exclusive patents for thermal vapor pulmonary treatments and the device has now been approved for marketing in major European countries and 12 Asia Pacific nations.PR NewswireBroncus Lists on Main Board of HKExBroncus, a medical device company specializing in interventional pulmonology, was successfully listed on the main board of the Hong Kong Stock Exchange on September 24, 2021. The company, founded in 2012, holds a leading position in China's interventional respiratory navigation equipment market with a 43.2% market share and offers core products including InterVapor, the world's first and only thermal vapor energy ablation system for lung diseases, and RF-II, the world's only radiofrequency ablation system focused on lung cancer. The IPO attracted recognition from investors including UBS Fund, Snow Lake Capital, and Exome Asset Management, with the company aiming to become a global leader in lung disease treatment.GlobeNewswireThe Global Pulmonary Endoscopy Devices Market is expected to grow from USD 4,823.13 Million in 2018 to USD 7,312.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.12%The global pulmonary endoscopy devices market is projected to grow from USD 4,823.13 million in 2018 to USD 7,312.13 million by 2025, a CAGR of 6.12%. The report covers major vendors including Boston Scientific, Broncus, and Medtronic, and divides the market by product type and geography.PR NewswireL'ablation par vapeur thermique sous bronchoscopie avec InterVapor® (BTVA®) est de retour sur le marchéUptake Medical Technology's Bronchoscopic Thermal Vapor Ablation (BTVA®) technology with InterVapor® has returned to the US market after a brief interruption caused by Broncus Holding Co. completing the sale of assets from Uptake Medical Corporation, with a new company incorporated in Seattle, Washington. The technology received a new CE marking based on significant clinical improvements in lung function and quality of life for severe emphysema patients, and treatments are now available in several European countries. The company plans to expand global BTVA sales to Australia and Asian countries by the end of 2017, while also conducting clinical studies on bronchoscopic lung cancer ablation.